Status:
UNKNOWN
COMPETE Cohort Study
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital
Conditions:
PFO - Patent Foramen Ovale
Migraine
Eligibility:
All Genders
18-65 years
Brief Summary
Migraine attacks are episodic disorder that affects approximately 12% of the population, and studies have shown that 41-48% of migraineurs have a combination of patent foramen ovale (PFO). Clinical Ob...
Eligibility Criteria
Inclusion
- Age 18-65 ；
- Diagnosed migraine by ICHD-3
- History of migraine longer than 1 year, and symptoms severely disturbing daily life.
- TCD/TTE/TEE diagnosed patent foramen ovale with right to left shunt
- Willing to participant and agree to follow-ups
- Received at least three different types of migraine preventive drugs, the responder rate of previous therapy did not receive 50%.
Exclusion
- Migraine caused by other reason
- Had TIA/stroke history
- With contraindication or hypersensitive to anti-platelet or anticoagulation drugs.
- With contraindication to PFO occlusion
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
242 Patients enrolled
Trial Details
Trial ID
NCT06033937
Start Date
January 1 2022
End Date
December 1 2025
Last Update
September 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuwai Hospital
Beijing, Beijing Municipality, China, 100028